Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-F33S in relapsed/refractory multiple myeloma
NCT07100067Recruiting
- Sponsor
- Legend Biotech Corporation
- Start
- Sep 2025
- Primary completion
- Feb 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of LCAR-F33S in multiple myeloma (MM), sponsored by Legend Biotech Corporation. Primary endpoints: Dose-Limiting Toxicity Rate at 30 days, Treatment-Emergent Adverse Events at 2 years and 5 more. Started Sep 2025; status: recruiting.
02
Drugs
LCAR-F33S
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07100067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07100067.